Quote:

---

CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS

---

Last time NP went one by one the subjects in the agenda. I expect this time he will do the same. There will be new development in some and not so much in others.

Some to put attention to will be Monotherapy and NASH (this latter could be the solution to financing, these trials ar lengthy, expensive and very difficult) as licesing Leronlimab for this condition could produce a good source of badly-needed capital.

Another interesting question will be the Three-Arm Comparative and Combination Trial between Leronlimab and Remdesivir. This was a very good move imo: take the battle to the "contender's" turf. Can't lose either way provided effectiveness is proven, and if we outperform everybody know where we stand.

This is not on the agenda and perhaps there is nothing new.

But, the question is what is the "meat" of the meeting. The "regulatory" reference in the announcement might be the key ...

Not much more to wait now ... Price should come up today in anticipation, and hopefully tomorrow in reaction.